Display options
Cite
Massengill JS, Kittredge JL. Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider. J Pain Res. 2014;7:125-32doi: 10.2147/JPR.S57242.
Massengill, J. S., & Kittredge, J. L. (2014). Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider. Journal of pain research, 7125-32. https://doi.org/10.2147/JPR.S57242
Massengill, Jamie S, and Kittredge, John L. "Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider." Journal of pain research vol. 7 (2014): 125-32. doi: https://doi.org/10.2147/JPR.S57242
Massengill JS, Kittredge JL. Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider. J Pain Res. 2014 Mar 10;7:125-32. doi: 10.2147/JPR.S57242. eCollection 2014. PMID: 24648752; PMCID: PMC3956687.
Copy Download .nbib Format: NLM
Share it on

J Pain Res. 2014 Mar 10;7:125-32. doi: 10.2147/JPR.S57242. eCollection 2014.

Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider.

Journal of pain research

Jamie S Massengill, John L Kittredge

Affiliations

  1. JSM Medical, Edmond, OK, USA.
  2. Michiana Spine, Sports and Occupational Rehab, PC, Mishawaka, IN, USA.

PMID: 24648752 PMCID: PMC3956687 DOI: 10.2147/JPR.S57242

Abstract

An estimated one million individuals in the US are diagnosed with herpes zoster (HZ; shingles) each year. Approximately 20% of these patients will develop postherpetic neuralgia (PHN), a complex HZ complication characterized by neuropathic pain isolated to the dermatome that was affected by the HZ virus. PHN is debilitating, altering physical function and quality of life, and commonly affects vulnerable populations, including the elderly and the immunocompromised. Despite the availability of an immunization for HZ prevention and several approved HZ treatments, the incidence of PHN is increasing. Furthermore, management of the neuropathic pain associated with PHN is often suboptimal, and the use of available therapeutics may be complicated by adverse effects and complex, burdensome treatment regimens, as well as by patients' comorbidities and polypharmacy, which may lead to drug-drug interactions. Informed and comprehensive assessments of currently available pharmacological treatment options to achieve effective pain control in the primary care setting are needed. In this article, we discuss the situation in clinical practice, review currently recommended prevention and treatment options for PHN, and outline practical considerations for the management of this neuropathic pain syndrome, with a focus on optimal, individual-based treatment plans for use in the primary care setting.

Keywords: clinical practice; herpes zoster; pharmacological treatment; postherpetic neuralgia; practical guidelines; primary care

References

  1. Pain Pract. 2014 Jan;14(1):E1-7 - PubMed
  2. JAMA Ophthalmol. 2013 Mar;131(3):396-8 - PubMed
  3. Clin Infect Dis. 2003 Apr 1;36(7):877-82 - PubMed
  4. Am J Clin Dermatol. 2013 Apr;14(2):77-85 - PubMed
  5. Vaccine. 2013 Mar 25;31(13):1680-94 - PubMed
  6. J Infect Dis. 1998 Nov;178 Suppl 1:S81-4 - PubMed
  7. J Am Osteopath Assoc. 2009 Jun;109(6 Suppl 2):S2-6 - PubMed
  8. Eur J Neurol. 2010 Sep;17(9):1113-e88 - PubMed
  9. Lancet. 2009 Oct 3;374(9696):1196-208 - PubMed
  10. Clin Geriatr Med. 2013 May;29(2):501-26 - PubMed
  11. J Fam Pract. 2012 Sep;61(9 Suppl):S9-15 - PubMed
  12. Arch Dermatol. 2011 Aug;147(8):901-7 - PubMed
  13. Clin Infect Dis. 2012 Nov 15;55(10):1320-8 - PubMed
  14. Int J Gen Med. 2012;5:861-71 - PubMed
  15. Hum Vaccin Immunother. 2013 May;9(5):1177-84 - PubMed
  16. Hosp Health Netw. 2013 Mar;87(3):45-52, 1 - PubMed
  17. Clin Ther. 1993 May-Jun;15(3):510-26 - PubMed
  18. Pain Pract. 2011 Jul-Aug;11(4):397-402 - PubMed
  19. Postgrad Med. 2013 Jul;125(4):191-202 - PubMed
  20. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005582 - PubMed
  21. Clin Drug Investig. 2012 Feb 22;32 Suppl 1:53-63 - PubMed
  22. Pain. 2013 Oct;154(10):2227-2233 - PubMed
  23. Neurology. 2004 Sep 28;63(6):959-65 - PubMed
  24. Dermatol Online J. 2012 Aug 15;18(8):2 - PubMed
  25. J Am Geriatr Soc. 2012 Apr;60(4):616-31 - PubMed
  26. Med Mal Infect. 2012 Feb;42(2):53-8 - PubMed
  27. Mayo Clin Proc. 2011 Dec;86(12):1146-53 - PubMed
  28. Pain. 2012 Apr;153(4):869-875 - PubMed
  29. Pain. 2008 Dec;140(3):395-396 - PubMed
  30. J Pain. 2009 Feb;10(2):113-30 - PubMed
  31. Vaccine. 2012 Apr 5;30(17):2795-800 - PubMed
  32. Clin Drug Investig. 2013 Jan;33(1):35-44 - PubMed
  33. J Pain. 2013 Jun;14(6):590-603 - PubMed
  34. Popul Health Manag. 2012 Dec;15(6):385-90 - PubMed
  35. Neurology. 2004 May 11;62(9):1545-51 - PubMed
  36. N Engl J Med. 2005 Jun 2;352(22):2271-84 - PubMed
  37. Clin Interv Aging. 2013;8:37-46 - PubMed
  38. Clin J Pain. 2010 Oct;26(8):656-66 - PubMed
  39. Clin Ther. 2003 Jan;25(1):81-104 - PubMed
  40. J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1372-3 - PubMed
  41. Am Fam Physician. 2011 Sep 15;84(6):690-2 - PubMed
  42. Neurology. 1998 Oct;51(4):1166-71 - PubMed
  43. J Pain Res. 2011;4:407-15 - PubMed
  44. Aging Clin Exp Res. 2009 Jun;21(3):236-43 - PubMed
  45. Am J Manag Care. 2013 Jan;19(1 Suppl):S207-13 - PubMed
  46. Cochrane Database Syst Rev. 2012 Oct 17;10:CD008858 - PubMed
  47. J Pain Res. 2012;5:203-8 - PubMed
  48. Pain Res Manag. 2009 Jul-Aug;14(4):275-82 - PubMed
  49. Mayo Clin Proc. 2010 Mar;85(3 Suppl):S3-14 - PubMed
  50. Pain. 2007 Nov;132 Suppl 1:S52-S59 - PubMed
  51. Age Ageing. 2013 Mar;42 Suppl 1:i1-57 - PubMed
  52. Am Fam Physician. 2011 Jun 15;83(12):1432-7 - PubMed

Publication Types